RTGN.US RetinalGenix Technologies Inc
- Market cap
- USD 75.2M
- P/E
- -
- P/B
- -
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is RTGN.US undervalued?
Graham numberThe Graham number of RetinalGenix Technologies Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
RetinalGenix Technologies Inc fundamental analysis
No fundamental analysis for RetinalGenix Technologies Inc yet.
RetinalGenix Technologies Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About RetinalGenix Technologies Inc
RetinalGeniX Technologies Inc., an ophthalmic research and development company, focuses on developing technologies to screen, monitor, diagnose, and treat ophthalmic, optical, and sight-threatening disorders. The company offers the Retinal Imaging Screening Device, a portable retinal imaging system providing a wide field of view without requiring pupil dilation; and RetinalCam, an in-home/remote location patient-activated monitoring and imaging device offering real-time comm…
Full company profileRetinalGenix Technologies Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
RetinalGenix Technologies Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Revenue | - | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | - | - | - | -362K | -371K | -404K | -704K | -639K | -287K |
| Operating Income | - | - | -2.08M | -2.18M | -3.91M | -2.09M | -4.32M | -2.42M | -1.79M |
| EBITDA | - | - | - | - | -3.91M | -2.09M | -4.32M | -2.42M | -1.78M |
| Net Income | - | - | -2.08M | -2.18M | -3.91M | -2.09M | -4.32M | -2.43M | -1.80M |
| EPS | - | - | -0.15 | -0.15 | -0.23 | -0.12 | -0.23 | -0.13 | -0.10 |
| Balance Sheet | |||||||||
| Total Assets | - | - | 61.1K | 4.95K | 294.00 | 156.00 | 14.9K | 21.0K | 32.2K |
| Total Liabilities | - | - | 141K | 470K | 1.07M | 1.41M | 1.48M | 2.32M | 2.67M |
| Shareholders' Equity | - | - | -80.4K | -465K | -1.07M | -1.41M | -1.46M | -2.30M | -2.64M |
| Cash & Short-term Investments | - | - | 2.22K | 4.95K | 38.00 | 0.00 | 6.06K | 14.8K | 27.2K |
| Cash Flow | |||||||||
| Operating Cash Flow | -157K | -157K | -1.42M | -1.17M | -199K | -452K | -742K | -558K | -492K |
| Capital Expenditure | 0.00 | 307.00 | 307.00 | 307.00 | 307.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | - | - | -1.42M | -1.17M | -200K | -452K | -742K | -558K | -492K |
| Ratios | |||||||||
| ROA | - | - | -3,402.4% | -44,052.8% | -1,331,289.1% | -1,340,313.5% | -28,909.6% | -11,542.2% | -5,574.3% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROA
- Return on assets: net income divided by total assets.
RetinalGenix Technologies Inc dividends
RetinalGenix Technologies Inc has not paid dividends in the last 8 fiscal years.
Who owns RetinalGenix Technologies Inc
- Insiders 65.30%
- Institutions 0.00%
- Public & others 34.71%
- Shares outstanding 18.8M
- Free float 7.06M
RetinalGenix Technologies Inc company profile
- Company name
- RetinalGenix Technologies Inc
- Ticker
- RTGN.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Fiscal year end
- December
- Address
- 409 Apollo Beach Boulevard, Apollo Beach, FL, United States, 33572
- Phone
- 415 578 9583
- Website
- retinalgenix.com
About RetinalGenix Technologies Inc
RetinalGeniX Technologies Inc., an ophthalmic research and development company, focuses on developing technologies to screen, monitor, diagnose, and treat ophthalmic, optical, and sight-threatening disorders. The company offers the Retinal Imaging Screening Device, a portable retinal imaging system providing a wide field of view without requiring pupil dilation; and RetinalCam, an in-home/remote location patient-activated monitoring and imaging device offering real-time communication and alerting system for physicians. It also develops RTG-2023 for the treatment of dry age-related macular degeneration; and RTG-2024 for the treatment of Alzheimer's syndrome dementia. The company was incorporated in 2017 and is based in Apollo Beach, Florida. RetinalGenix Technologies Inc. is a subsidiary of Sanovas Ophthalmology, LLC.
RetinalGenix Technologies Inc management
1- Dr. Jerry Katzman M.D.CEO, President, Interim CFO & Chairman · born 1953